)
| Adverse reaction |
BOREAS and NOTUS | |
|---|---|---|
| DUPIXENT 300 mg Q2W n=938 n (%) |
Placebo n=934 n (%) |
|
| Viral infectiona | 133 (14.2) | 115 (12.3) |
| Headache | 73 (7.8) | 62 (6.6) |
| Nasopharyngitis | 73 (7.8) | 69 (7.4) |
| Back pain | 42 (4.5) | 29 (3.1) |
| Diarrheaa | 35 (3.7) | 30 (3.2) |
| Arthralgia | 29 (3.1) | 25 (2.7) |
| Urinary tract infection | 28 (3.0) | 18 (1.9) |
| Local administration reactions | 26 (2.8) | 6 (0.6) |
| Injection site reactions | 11 (1.2) | 2 (0.2) |
| Rhinitis | 24 (2.6) | 17 (1.8) |
| Eosinophiliab | 22 (2.3) | 7 (0.7) |
| Toothache | 20 (2.1) | 11 (1.2) |
| Gastritis | 19 (2) | 7 (0.7) |
aConsists of multiple similar terms.
bEosinophilia was defined as blood eosinophils ≥3000 cells/μL or deemed by the investigator to be an adverse event. None met the criteria for serious
eosinophilic conditions.
Explore the complete study designs
Discover the full studydesigns
Learn more about dosage and administration
options for patients on DUPIXENT
FREQUENTLY ASKED QUESTIONS
The most common adverse reactions (incidence ≥2%) are viral infection, headache, nasopharyngitis, back pain, diarrhea, arthralgia, urinary tract infection, local administration reaction, rhinitis, eosinophilia, toothache, and gastritis.1
COPD, chronic obstructive pulmonary disease.